Lu-DOTA-TATE (Lutetium-177 DOTATATE)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Lu-DOTA-TATE (Lutetium-177 DOTATATE), covering 2024-10-15 to 2024-10-15. Get the full timeline:
Most recent: Clinical Trial Update: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours [Phase 2]